Status of research on endocapillary proliferation lesion in IgA nephropathy

doi:10.3877/cma.j.issn.2095-3216.2016.05.010

Abstract

Abstract:

IgA nephropathy (IgAN) is a primary glomerular disease characterized by mesangial proliferation, as well as varying degrees of endocapillary proliferative lesion. The authors reviewed studies about endocapillary proliferative lesion of IgAN and summarized the clinical and pathological characteristics and the prognosis of IgAN patients presented with endocapillary proliferation, in order to clarify the clinical significance of endocapillary proliferation lesion in IgAN.

Key words: IgA nephrology, Endocapillary proliferation, Evidence-based medicine

Hongyu Yang, Jicheng Lv, Hong Zhang. Status of research on endocapillary proliferation lesion in IgA nephropathy[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2016, 05(05): 232-237.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2016.05.010

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2016/V05/I05/232

Figures/Tables 1

References 50

1	Wyatt RJ, Julian BA. IgA nephropathy [J]. N Engl J Med, 2013，368(25):2402-2414.
2	Donadio JV, Grande JP. IgA nephropathy [J]. N Engl J Med, 2002，347(10):738-748.
3	Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13，519 renal biopsies [J]. Kidney Int, 2004, 66(3):920-923.
4	Zhou FD, Zhao MH, Zou WZ, et al. The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre [J]. Nephrol Dial Transplant, 2009, 24(3):870-876.
5	Wang H, Zhang L, Lv J. Prevention of the progression of chronic kidney disease: practice in China [J]. Kidney Int, 2005，Suppl(94):S63-S67.
6	Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification [J]. Kidney Int, 2009，76(5):534-545.
7	El Karoui K, Hill GS, Karras A, et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies [J]. Kidney Int, 2011, 79(6):643-654.
8	Alamartine E, Sauron C, Laurent B, et al. The use of the Oxford classification of IgA nephropathy to predict renal survival [J]. Clin J Am Soc Nephrol, 2011, 6(10):2384-2388.
9	Kang SH, Choi SR, Park HS, et al. The Oxford classification as a predictor of prognosis in patients with IgA nephropathy [J]. Nephrol Dial Transplant, 2012, 27(1):252-258.
10	Herzenberg AM, Fogo AB, Reich HN, et al. Validation of the Oxford classification of IgA nephropathy [J]. Kidney Int, 2011, 80(3):310-317.
11	Yau T, Korbet SM, Schwartz MM, et al. The Oxford classification of IgA nephropathy: a retrospective analysis [J]. Am J Nephrol, 2011, 34(5):435-444.
12	Edstrom Halling S, Soderberg MP, Berg UB. Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification) [J]. Nephrol Dial Transplant, 2012, 27(2):715-722.
13	Shi SF, Wang SX, Jiang L, et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification [J]. Clin J Am Soc Nephrol, 2011, 6(9):2175-2184.
14	Zeng CH, Le W, Ni Z, et al. A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult chinese patients [J]. Am J Kidney Dis, 2012, 60(5):812-820.
15	Shima Y, Nakanishi K, Hama T, et al. Validity of the Oxford classification of IgA nephropathy in children [J]. Pediatr Nephrol, 2012, 27(5):783-792.
16	Katafuchi R, Ninomiya T, Nagata M, et al. Validation study of Oxford classification of IgA nephropathy: the significance of extracapillary proliferation [J]. Clin J Am Soc Nephrol, 2011, 6(12):2806-2813.
17	Gutierrez E, Zamora I, Ballarin JA, et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria [J]. J Am Soc Nephrol, 2012, 23(10):1753-1760.
18	Kataoka H, Ohara M, Shibui K, et al. Overweight and obesity accelerate the progression of IgA nephropathy: prognostic utility of a combination of BMI and histopathological parameters [J]. Clin Exp Nephrol, 2012，16(5):706-712.
19	Le W, Zeng CH, Liu Z, et al. Validation of the Oxford classification of IgA nephropathy for pediatric patients from China [J]. BMC Nephrol, 2012, 13:158.
20	Lee H, Yi SH, Seo MS, et al. Validation of the Oxford classification of IgA nephropathy: a single-center study in Korean adults [J]. Korean J Intern Med, 2012, 27(3):293-300.
21	Moriyama T, Nakayama K, Iwasaki C, et al. Severity of nephrotic IgA nephropathy according to the Oxford classification [J]. Int Urol Nephrol, 2012, 44(4):1177-1184.
22	Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments [J]. Kidney Int, 2014，86(4):828-836.
23	Liu LJ, Li GT, Zhou Y, et al. Clinicopathologic features and outcomes in endocapillary proliferative IgA nephropathy [J]. Nephron Clin Pract, 2010，115(2):c161-c167.
24	Hisano S, Kiyoshi Y, Tanaka I, et al. Clinicopathological correlation of childhood IgA glomerulonephritis presenting diffuse endocapillary proliferation [J]. Pathol Int，2004，54(3):174-180.
25	Allen AC, Bailey EM, Brenchley PE, et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients [J]. Kidney Int, 2001, 60(3):969-973.
26	Hiki Y, Odani H, Takahashi M, et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy [J]. Kidney Int, 2001, 59(3):1077-1085.
27	Barratt J, Feehally J, Smith AC. Pathogenesis of IgA nephropathy [J]. Semin Nephrol, 2004, 24(3):197-217.
28	Smith AC, Molyneux K, Feehally J, et al. O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy [J]. J Am Soc Nephrol, 2006，17(12):3520-3528.
29	Novak J, Julian BA, Tomana M, et al. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy [J]. Semin Nephrol, 2008, 28(1):78-87.
30	Suzuki H, Moldoveanu Z, Hall S, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1 [J]. J Clin Invest, 2008，118(2):629-639.
31	Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity [J]. J Clin Invest, 2009，119(6):1668-1677.
32	Kokubo T, Hiki Y, Iwase H, et al. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins [J]. J Am Soc Nephrol, 1998, 9(11):2048-2054.
33	Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies [J]. J Clin Invest, 1999，104(1):73-81.
34	Lai KN, Tang SC, Guh JY, et al. Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin-angiotensin system [J]. J Am Soc Nephrol, 2003，14(12):3127-3137.
35	van den Dobbelsteen ME, van der Woude FJ, Schroeijers WE, et al. Binding of dimeric and polymeric IgA to rat renal mesangial cells enhances the release of interleukin 6 [J]. Kidney Int, 1994，46(2):512-519.
36	Terada Y, Yamada T, Nakashima O, et al. Expression of PDGF and PDGF receptor mRNA in glomeruli in IgA nephropathy [J]. J Am Soc Nephrol，1997, 8(5):817-819.
37	Maillard N, Wyatt RJ, Julian BA, et al. Current understanding of the role of complement in IgA nephropathy [J]. J Am Soc Nephrol, 2015, 26(7):1503-1512.
38	Chan LY, Leung JC, Tsang AW, et al. Activation of tubular epithelial cells by mesangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy [J]. Kidney Int, 2005, 67(2):602-612.
39	Zhu L, Zhang Q, Shi S, et al. Synergistic effect of mesangial cell-induced CXCL1 and TGF-beta1 in promoting podocyte loss in IgA nephropathy [J]. PloS One, 2013, 8(8):e73425.
40	Hodgin JB, Berthier CC, John R, et al. The molecular phenotype of endocapillary proliferation: novel therapeutic targets for IgA nephropathy [J]. PloS One, 2014, 9(8):e103413.
41	Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis [J]. Science, 1995, 270(5234):286-290.
42	Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids [J]. Science, 1995，270(5234):283-286.
43	Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Coppo R, Troyanov S, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults [J]. Kidney Int, 2010, 77(10):921-927.
44	周杨，张宏，吕继成，等. 以毛细血管内皮细胞增生为主要特点的IgA肾病的治疗[J]. 现代实用医学，2006，18(8):541-543.
45	陈敏广，龚一女，杨青，等. 伴弥漫型毛细血管内增生的儿童原发性IgA肾病临床病理分析[J]. 中华肾脏病杂志，2012，28(3):2.
46	周扬，张宏，陈育青，等. 毛细血管内皮细胞增生性IgA肾病的临床特点和预后分析[J]. 现代实用医学，2011, 23(10):2.
47	Lv J, Shi S, Xu D, et al. Evaluation of the Oxford classification of IgA nephropathy: a systematic review and meta-analysis [J]. Am J Kidney Dis, 2013, 62(5):891-899.
48	D′Amico G, Minetti L, Ponticelli C, et al. Prognostic indicators in idiopathic IgA mesangial nephropathy [J]. Q J Med, 1986，59(228):363-378.
49	Chakera A, MacEwen C, Bellur SS, et al. Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression [J]. J Nephrol, 2016, 29(3):367-375.
50	Tesar V, Troyanov S, Bellur S, et al. Corticosteroids in IgA Nephropathy: a retrospective analysis from the VALIGA study [J]. J Am Soc Nephrol, 2015, 26(9):2248-2258.

研究来源	时间(年)	种族(%)	设计	样本量(例)	随访(月)	年龄(岁)	儿童(%)	男：女	蛋白尿(g/d)
牛津队列^[19](多国家)	2009	白人66,亚洲人27,黑人3,其他4	多中心	265	65.0	30.0	22.3	2.6∶1.0	1.7
Karoui^[3](法国)	2011	白人92.2,亚洲人7.8	多中心	128	44.0	38.7	0.0	2.1∶1.0	2.4
Alamarine^[4](法国)	2011	NA	单中心	183	77.0	38.0	NA	3.0∶1.0	1.2
Kang^[5](韩国)	2012	亚洲人100	单中心	197	56.8	32.4	NA	1.4∶1.0	2.1
Herzenberg^[6](北美)	2011	白人69,亚洲人20 黑人5,其他6	多中心	187	53.0	34.0	24.0	1.3∶1.0	1.7
Yau^[7](美国)	2011	白人50,亚洲人26 黑人6,其他19	单中心	54	7	41	NA	1.4∶1.0	2.0
Halling^[8](瑞典)	2012	NA	单中心	99	156.0	9.7	100.0	1.4∶1.0	2.0
Shi^[9](中国)	2011	亚洲人100	单中心	410	38.0	31.0	0.0	1.0∶1.0	1.7
Zeng^[10](中国)	2012	亚洲人100	多中心	1026	53.0	34.0	0.0	1.0∶1.0	1.3
Shima^[11](日本)	2012	亚洲人100	多中心	161	54.0	11.7	100.0	1.7∶1.0	0.7
Katafuchi^[12](日本)	2011	亚洲人100	单中心	702	62.0	30.0	NA	1.0∶1.2	0.9
Gutierrez^[13](西班牙)	2012	白人100	多中心	141	108.0	23.7	NA	1.8∶1.0	0.2
Kataoka^[14](日本)	2012	亚洲人100	单中心	43	120.0	40.0	0.0	1.5∶1.0	1.8
Le^[15](中国)	2012	亚洲人100	多中心	218	56.0	14.0	100.0	1.9∶1.0	1.5
Lee^[16](韩国)	2012	亚洲人100	单中心	69	85.0	34.0	0.0	1.4∶1.0	1.2
Moriyama^[17](日本)	2012	亚洲人100	单中心	42	NA	34.2	0.0	1.0∶1.0	5.7
Coppo^[18](欧洲)	2014	白人97.5,亚洲人0.5 黑人0.5,其他1	多中心	1147	53.0	36.0	15.0	2.7∶1.0	1.3
研究来源	时间(年)	eGFR (ml/min)	CKD分期(1/2/3/4/5，例)	高血压(%)	免疫抑制治疗(%)	ESRD(例)	E1病变(%)	E1与预后	E1对免疫抑制治疗反应
牛津队列^[19](多国家)	2009	83.0	36/38/26/0/0	31.0	29.0	34	42.0	无统计学差异	反应良好
Karoui^[3](法国)	2011	52.1	NA	NA	0.8	35	25.0	提示预后不良	NA
Alamarine^[4](法国)	2011	72.0	28/34/19/7/6	38.0	30.0	30	14.0	提示预后不良	NA
Kang^[5](韩国)	2012	87.1	NA	24.4	38.0	NA	11.0	无统计学差异	NA
Herzenberg^[6](北美)	2011	82.0	NA	58.0	41.0	21	NA	无统计学差异	反应良好
Yau^[7](美国)	2011	61.0	54(1＋2)/30/15/2	48.0	35.0	7	20.0	NA	NA
Halling^[8](瑞典)	2012	10.0	75/16/4/3/2	NA	43.0	15	10.0	提示预后不良	NA
Shi^[9](中国)	2011	85.8	43/38/19/0/0	NA	42.7	30	57.0	无统计学差异	反应良好
Zeng^[10](中国)	2012	85.0	41/35/24/0/0	30.5	31.0	38	11.0	无统计学差异	无统计学差异
Shima^[11](日本)	2012	103.0	NA	NA	16.0	5	58.0	提示预后不良	NA
Katafuchi^[12](日本)	2011	82.0	37/37/21/3/1	NA	32.0	84	42.0	无统计学差异	NA
Gutierrez^[13](西班牙)	2012	111.7	10(1＋2)/0/0/0	16.3	0.0	0	9.0	NA	NA
Kataoka^[14](日本)	2012	78.3	NA	NA	51.2	NA	53.0	NA	NA
Le^[15](中国)	2012	134.0	NA	NA	56.0	NA	23.0	无统计学差异	NA
Lee^[16](韩国)	2012	90.8	NA	94.0	18.3	NA	32.0	提示预后不良	NA
Moriyama^[17](日本)	2012	51.1	NA	NA	64.2	24	43.0	无统计学差异	NA
Coppo^[18](欧洲)	2014	73.0	60(1＋2)/28/7/2	65.0	10.0	135	11.0	无统计学差异	无统计学差异

研究来源	时间(年)	种族(%)	设计	样本量(例)	随访(月)	年龄(岁)	儿童(%)	男：女	蛋白尿(g/d)
牛津队列^[19](多国家)	2009	白人66,亚洲人27,黑人3,其他4	多中心	265	65.0	30.0	22.3	2.6∶1.0	1.7
Karoui^[3](法国)	2011	白人92.2,亚洲人7.8	多中心	128	44.0	38.7	0.0	2.1∶1.0	2.4
Alamarine^[4](法国)	2011	NA	单中心	183	77.0	38.0	NA	3.0∶1.0	1.2
Kang^[5](韩国)	2012	亚洲人100	单中心	197	56.8	32.4	NA	1.4∶1.0	2.1
Herzenberg^[6](北美)	2011	白人69,亚洲人20 黑人5,其他6	多中心	187	53.0	34.0	24.0	1.3∶1.0	1.7
Yau^[7](美国)	2011	白人50,亚洲人26 黑人6,其他19	单中心	54	7	41	NA	1.4∶1.0	2.0
Halling^[8](瑞典)	2012	NA	单中心	99	156.0	9.7	100.0	1.4∶1.0	2.0
Shi^[9](中国)	2011	亚洲人100	单中心	410	38.0	31.0	0.0	1.0∶1.0	1.7
Zeng^[10](中国)	2012	亚洲人100	多中心	1026	53.0	34.0	0.0	1.0∶1.0	1.3
Shima^[11](日本)	2012	亚洲人100	多中心	161	54.0	11.7	100.0	1.7∶1.0	0.7
Katafuchi^[12](日本)	2011	亚洲人100	单中心	702	62.0	30.0	NA	1.0∶1.2	0.9
Gutierrez^[13](西班牙)	2012	白人100	多中心	141	108.0	23.7	NA	1.8∶1.0	0.2
Kataoka^[14](日本)	2012	亚洲人100	单中心	43	120.0	40.0	0.0	1.5∶1.0	1.8
Le^[15](中国)	2012	亚洲人100	多中心	218	56.0	14.0	100.0	1.9∶1.0	1.5
Lee^[16](韩国)	2012	亚洲人100	单中心	69	85.0	34.0	0.0	1.4∶1.0	1.2
Moriyama^[17](日本)	2012	亚洲人100	单中心	42	NA	34.2	0.0	1.0∶1.0	5.7
Coppo^[18](欧洲)	2014	白人97.5,亚洲人0.5 黑人0.5,其他1	多中心	1147	53.0	36.0	15.0	2.7∶1.0	1.3
研究来源	时间(年)	eGFR (ml/min)	CKD分期(1/2/3/4/5，例)	高血压(%)	免疫抑制治疗(%)	ESRD(例)	E1病变(%)	E1与预后	E1对免疫抑制治疗反应
牛津队列^[19](多国家)	2009	83.0	36/38/26/0/0	31.0	29.0	34	42.0	无统计学差异	反应良好
Karoui^[3](法国)	2011	52.1	NA	NA	0.8	35	25.0	提示预后不良	NA
Alamarine^[4](法国)	2011	72.0	28/34/19/7/6	38.0	30.0	30	14.0	提示预后不良	NA
Kang^[5](韩国)	2012	87.1	NA	24.4	38.0	NA	11.0	无统计学差异	NA
Herzenberg^[6](北美)	2011	82.0	NA	58.0	41.0	21	NA	无统计学差异	反应良好
Yau^[7](美国)	2011	61.0	54(1＋2)/30/15/2	48.0	35.0	7	20.0	NA	NA
Halling^[8](瑞典)	2012	10.0	75/16/4/3/2	NA	43.0	15	10.0	提示预后不良	NA
Shi^[9](中国)	2011	85.8	43/38/19/0/0	NA	42.7	30	57.0	无统计学差异	反应良好
Zeng^[10](中国)	2012	85.0	41/35/24/0/0	30.5	31.0	38	11.0	无统计学差异	无统计学差异
Shima^[11](日本)	2012	103.0	NA	NA	16.0	5	58.0	提示预后不良	NA
Katafuchi^[12](日本)	2011	82.0	37/37/21/3/1	NA	32.0	84	42.0	无统计学差异	NA
Gutierrez^[13](西班牙)	2012	111.7	10(1＋2)/0/0/0	16.3	0.0	0	9.0	NA	NA
Kataoka^[14](日本)	2012	78.3	NA	NA	51.2	NA	53.0	NA	NA
Le^[15](中国)	2012	134.0	NA	NA	56.0	NA	23.0	无统计学差异	NA
Lee^[16](韩国)	2012	90.8	NA	94.0	18.3	NA	32.0	提示预后不良	NA
Moriyama^[17](日本)	2012	51.1	NA	NA	64.2	24	43.0	无统计学差异	NA
Coppo^[18](欧洲)	2014	73.0	60(1＋2)/28/7/2	65.0	10.0	135	11.0	无统计学差异	无统计学差异

[1]	Tianzhu Long, Yuzhi Yao, Jiayue Luo, Yuanxuan Cai, Zhen Liang, Zhe Fan, Cairong Zhu, Yuhong Pan, Hongmin Ma. Antibiotic treatment for lactational breast abscess: a retrospective study [J]. Chinese Journal of Breast Disease(Electronic Edition), 2021, 15(04): 214-217.
[2]	Xiaowei Qi, Xiaoyu Wang, Yanling Li, Ying Hu, Wenting Yan, Long Yuan, Xuanni Tan, Qinwen Pan, Lin Ren, Ling Zhong, Qingqiu Chen, Ting Zhang, Kongyong Zhang, Jun Jiang. Application of evidence-based medicine in undergraduate education to improve scientific research ability [J]. Chinese Journal of Breast Disease(Electronic Edition), 2018, 12(02): 100-103.
[3]	The Joint Surgery Branch of the Chinese Orthopaedic Association, 920th Hospital of Joint Logistics Support Force of Chinese People′s Liberation Army. Chinese clinical practice guidelines for total hip arthroplasty approach selection (2021 edition) [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2021, 15(06): 651-659.
[4]	Dan Xing, Jianhao Lin. Real-world research in developing clinical practice guidelines for osteoarthritis [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2018, 12(01): 91-95.
[5]	Chunsong Yang, Lingli Zhang, Hong Huang, Cairong Zhu. Research progress on antiepileptic drugs in the treatment of Tourette's syndrome in children [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2015, 11(03): 407-410.
[6]	Haiwei Wu, Jiawei Zheng. Evidence-based treatment algorithms for vascular malformations of the head and neck [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2016, 10(04): 231-237.
[7]	Qian Liu. The clinical status of lateral lymph node dissection for rectal cancer in China [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2022, 11(05): 367-371.
[8]	Ying Zheng, Jinling Meng, Guangyan Cai, Zhe Feng. Practice and thinking of blended learning mode in evidence-based medicine course for professional degree postgraduates in nephrology [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(01): 48-50.
[9]	Li Zhang. Exploration of multidimensional teaching of clinical practice guidelines for kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2019, 08(02): 78-81.
[10]	Yachun Han, Lin Sun. New advancements of evidenced-based medical treatment of diabetic nephropathy [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(05): 251-256.
[11]	Zongsheng Wu, Jianfeng Xie, Haibo Qiu. Surviving sepsis campaign guidelines 2021: “eight pitfalls” in early resuscitation [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2023, 09(01): 14-18.
[12]	Dechang Chen. From the past to the present and the future: the 20 anniversary of the establishment of the Chinese Society of Critical Care Medicine [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2016, 02(03): 145-148.
[13]	Jinquan Wang. Clinical thinking in the treatment of critically ill patients [J]. Chinese Journal of Diagnostics(Electronic Edition), 2017, 05(01): 42-45.
[14]	Dong Wu. Clinical thinking and its dynamic characteristics [J]. Chinese Journal of Diagnostics(Electronic Edition), 2015, 03(02): 90-97.
[15]	Xiaoling Wang, Ting Yang, Zhuanye Yin, Ying Zhang. Evidence summary of identification and prevention of post-stroke depression [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(01): 51-56.

Please choose a citation manager

Content to export